Protalix Surges with European Approval and Revenue Boost

Protalix BioTherapeutics is having a good start to 2026, with a solid revenue boost from a $25 million milestone payment after their drug Elfabrio got the green light in Europe. They're sticking to their revenue goals for the year and are pumped about their ongoing clinical trials for PRX-115, which is aimed at treating uncontrolled gout. Their financials are looking strong with $51 million in cash, and they're excited about the future growth in rare disease treatments. What does it mean for you? If you're keeping an eye on the biotech sector or investing in companies working on rare disease treatments, Protalix is one to watch. Their recent successes could mean strong growth potential, giving investors something to cheer about.